📧 Communication
Warning to InvestorsCommunication Details
From
Celgene
Linked to Celgene
To
Investors
local and regional investors
Subject
Future dependency on Thalomid
Message Content
Celgene warned investors that the company would be 'very dependent on the commercial success of Thalomid' and that its approved market was 'relatively small'.
📄 Source Document
HOUSE_OVERSIGHT_028418.jpg
ESTATE Collection
Document Summary
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein communication